{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:09:38Z","timestamp":1783904978634,"version":"3.55.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ministry of Health, Labour and Welfare, Japan","award":["23FA1020"],"award-info":[{"award-number":["23FA1020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-53112-3","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T18:18:03Z","timestamp":1778609883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sub-tenon triamcinolone acetonide injections in diabetic macular edema: analyzing interstitial fluid glucose fluctuations with continuous monitoring technology"],"prefix":"10.1038","volume":"16","author":[{"given":"Yoshiaki","family":"Chiku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Hoshiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"53112_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"R Lee","year":"2015","unstructured":"Lee, R., Wong, T. Y. & Sabanayagam, C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. (Lond). 2, 17. https:\/\/doi.org\/10.1186\/s40662-015-0026-2 (2015).","journal-title":"Eye Vis. (Lond)"},{"key":"53112_CR2","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1210\/clinem\/dgad581","volume":"109","author":"SH Ou","year":"2024","unstructured":"Ou, S. H. et al. Diabetic Macular Edema Is Predictive of Renal Failure in Patients With Diabetes Mellitus and Chronic Kidney Disease. J. Clin. Endocrinol. Metab. 109, 761\u2013770. https:\/\/doi.org\/10.1210\/clinem\/dgad581 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"53112_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12902-022-01161-w","volume":"22","author":"A Oraii","year":"2022","unstructured":"Oraii, A. et al. Prevalence, awareness, treatment, and control of type 2 diabetes mellitus among the adult residents of tehran: Tehran Cohort Study. BMC Endocr. Disord. 22, 248. https:\/\/doi.org\/10.1186\/s12902-022-01161-w (2022).","journal-title":"BMC Endocr. Disord"},{"key":"53112_CR4","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.4103\/ijo.IJO_1240_18","volume":"66","author":"DJ Browning","year":"2018","unstructured":"Browning, D. J., Stewart, M. W. & Lee, C. Diabetic macular edema: Evidence-based management. Indian J. Ophthalmol. 66, 1736\u20131750. https:\/\/doi.org\/10.4103\/ijo.IJO_1240_18 (2018).","journal-title":"Indian J. Ophthalmol."},{"key":"53112_CR5","doi-asserted-by":"publisher","unstructured":"Tatsumi, T., Oshitari, T., Baba, T., Takatsuna, Y. & Yamamoto, S. Effects of Switching from Anti-VEGF Treatment to Triamcinolone Acetonide in Eyes with Refractory Macular Edema Associated with Diabetic Retinopathy or Retinal Vein Occlusion. Biomed. Res. Int. 2020 (4529850). https:\/\/doi.org\/10.1155\/2020\/4529850 (2020).","DOI":"10.1155\/2020\/4529850"},{"key":"53112_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3341\/kjo.2016.30.1.25","volume":"30","author":"MW Kim","year":"2016","unstructured":"Kim, M. W., Moon, H., Yang, S. J. & Joe, S. G. Effect of Posterior Subtenon Triamcinolone Acetonide Injection on Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Injection. Korean J. Ophthalmol. 30, 25\u201331. https:\/\/doi.org\/10.3341\/kjo.2016.30.1.25 (2016).","journal-title":"Korean J. Ophthalmol."},{"key":"53112_CR7","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3341\/kjo.2006.20.4.205","volume":"20","author":"YJ Choi","year":"2006","unstructured":"Choi, Y. J., Oh, I. K., Oh, J. R. & Huh, K. Intravitreal versus posterior subtenon injection of triamcinolone acetonide for diabetic macular edema. Korean J. Ophthalmol. 20, 205\u2013209. https:\/\/doi.org\/10.3341\/kjo.2006.20.4.205 (2006).","journal-title":"Korean J. Ophthalmol."},{"key":"53112_CR8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s12886-022-02625-2","volume":"22","author":"M Khalil","year":"2022","unstructured":"Khalil, M., Mansour, H. O., Tawfik, A. M. R. & Elmahdy, A. G. Comparison between intravitreal ranibizumab injection and posterior subtenon triamcinolone acetonide injection at time of cataract surgery for prevention of progression of diabetic macular edema. BMC Ophthalmol. 22, 492. https:\/\/doi.org\/10.1186\/s12886-022-02625-2 (2022).","journal-title":"BMC Ophthalmol."},{"key":"53112_CR9","doi-asserted-by":"publisher","first-page":"10901","DOI":"10.1038\/s41598-023-37726-5","volume":"13","author":"T Hirano","year":"2023","unstructured":"Hirano, T. et al. Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study. Sci. Rep. 13, 10901. https:\/\/doi.org\/10.1038\/s41598-023-37726-5 (2023).","journal-title":"Sci. Rep."},{"key":"53112_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s10384-021-00820-0","volume":"65","author":"T Hirano","year":"2021","unstructured":"Hirano, T. et al. Treat-and-extend therapy with aflibercept for diabetic macular edema: a prospective clinical trial. Jpn J. Ophthalmol. 65, 354\u2013362. https:\/\/doi.org\/10.1007\/s10384-021-00820-0 (2021).","journal-title":"Jpn J. Ophthalmol."},{"key":"53112_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12886-020-01637-0","volume":"20","author":"JM Ruiz-Moreno","year":"2020","unstructured":"Ruiz-Moreno, J. M., de Andr\u00e9s-Nogales, F. & Oyag\u00fcez, I. Cost-consequence analysis of extended loading dose of anti-VEGF treatment in diabetic macular edema patients. BMC Ophthalmol. 20, 371. https:\/\/doi.org\/10.1186\/s12886-020-01637-0 (2020).","journal-title":"BMC Ophthalmol."},{"key":"53112_CR12","doi-asserted-by":"publisher","first-page":"101788","DOI":"10.1016\/j.ajoc.2022.101788","volume":"29","author":"T Hirano","year":"2023","unstructured":"Hirano, T., Toriyama, Y., Takahashi, Y., Hoshiyama, K. & Murata, T. Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema. Am. J. Ophthalmol. Case Rep. 29, 101788. https:\/\/doi.org\/10.1016\/j.ajoc.2022.101788 (2023).","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"53112_CR13","doi-asserted-by":"publisher","first-page":"1225e1221","DOI":"10.1016\/j.ophtha.2009.02.031","volume":"116","author":"KS Klein","year":"2009","unstructured":"Klein, K. S. et al. Endophthalmitis after anti-VEGF injections. Ophthalmology 116, 1225e1221. https:\/\/doi.org\/10.1016\/j.ophtha.2009.02.031 (2009).","journal-title":"Ophthalmology"},{"key":"53112_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/1060028017728297","volume":"52","author":"MD Wallace","year":"2018","unstructured":"Wallace, M. D. & Metzger, N. L. Optimizing the Treatment of Steroid-Induced Hyperglycemia. Ann. Pharmacother. 52, 86\u201390. https:\/\/doi.org\/10.1177\/1060028017728297 (2018).","journal-title":"Ann. Pharmacother"},{"key":"53112_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.diabres.2018.03.006","volume":"139","author":"A Bonaventura","year":"2018","unstructured":"Bonaventura, A. & Montecucco, F. Steroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res. Clin. Pract. 139, 203\u2013220. https:\/\/doi.org\/10.1016\/j.diabres.2018.03.006 (2018).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"53112_CR16","doi-asserted-by":"publisher","first-page":"e00308","DOI":"10.1002\/edm2.308","volume":"5","author":"S Sharma","year":"2022","unstructured":"Sharma, S., Karki, P., Joshi, S. N. & Parajuli, S. Influence of glycaemic control on macular thickness in diabetic retinopathy. Endocrinol. Diabetes Metab. 5, e00308. https:\/\/doi.org\/10.1002\/edm2.308 (2022).","journal-title":"Endocrinol. Diabetes Metab."},{"key":"53112_CR17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/ceo.13728","volume":"48","author":"YT Hsieh","year":"2020","unstructured":"Hsieh, Y. T. & Hsieh, M. C. Fasting plasma glucose variability is an independent risk factor for diabetic retinopathy and diabetic macular oedema in type 2 diabetes: An 8-year prospective cohort study. Clin. Exp. Ophthalmol. 48, 470\u2013476. https:\/\/doi.org\/10.1111\/ceo.13728 (2020).","journal-title":"Clin. Exp. Ophthalmol."},{"key":"53112_CR18","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1056\/NEJMoa2205650","volume":"387","author":"L Leelarathna","year":"2022","unstructured":"Leelarathna, L. et al. Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes. N Engl. J. Med. 387, 1477\u20131487. https:\/\/doi.org\/10.1056\/NEJMoa2205650 (2022).","journal-title":"N Engl. J. Med."},{"key":"53112_CR19","doi-asserted-by":"publisher","unstructured":"Fellinger, E., Brandt, T., Creutzburg, J., Rommerskirchen, T. & Schmidt, A. Analytical Performance of the FreeStyle Libre 2 Glucose Sensor in Healthy Male Adults. Sens. (Basel). 24. https:\/\/doi.org\/10.3390\/s24175769 (2024).","DOI":"10.3390\/s24175769"},{"key":"53112_CR20","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/bjo.2009.172106","volume":"94","author":"K Nan","year":"2010","unstructured":"Nan, K. et al. Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection. Br. J. Ophthalmol. 94, 654\u2013658. https:\/\/doi.org\/10.1136\/bjo.2009.172106 (2010).","journal-title":"Br. J. Ophthalmol."},{"key":"53112_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ajo.2009.03.031","volume":"148","author":"S Zaka-ur-Rab","year":"2009","unstructured":"Zaka-ur-Rab, S. et al. Systemic absorption of triamcinolone acetonide after posterior sub-Tenon injection. Am. J. Ophthalmol. 148, 414\u2013419. https:\/\/doi.org\/10.1016\/j.ajo.2009.03.031 (2009).","journal-title":"Am. J. Ophthalmol."},{"key":"53112_CR22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ajo.2011.10.021","volume":"153","author":"K Kovacs","year":"2012","unstructured":"Kovacs, K. et al. Pharmacokinetic study of vitreous and serum concentrations of triamcinolone acetonide after posterior sub-tenon\u2019s injection. Am. J. Ophthalmol. 153, 939\u2013948. https:\/\/doi.org\/10.1016\/j.ajo.2011.10.021 (2012).","journal-title":"Am. J. Ophthalmol."},{"key":"53112_CR23","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s13300-023-01393-6","volume":"14","author":"HL Barker","year":"2023","unstructured":"Barker, H. L., Morrison, D., Llano, A., Sainsbury, C. A. R. & Jones, G. C. Practical Guide to Glucocorticoid Induced Hyperglycaemia and Diabetes. Diabetes Ther. 14, 937\u2013945. https:\/\/doi.org\/10.1007\/s13300-023-01393-6 (2023).","journal-title":"Diabetes Ther."},{"key":"53112_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/iovs.17-22259","volume":"59","author":"SM Whitcup","year":"2018","unstructured":"Whitcup, S. M., Cidlowski, J. A., Csaky, K. G. & Ambati, J. Pharmacology of Corticosteroids for Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 59, 1\u201312. https:\/\/doi.org\/10.1167\/iovs.17-22259 (2018).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"53112_CR25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","volume":"18","author":"JX Li","year":"2022","unstructured":"Li, J. X. & Cummins, C. L. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat. Rev. Endocrinol. 18, 540\u2013557. https:\/\/doi.org\/10.1038\/s41574-022-00683-6 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"53112_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-024-02347-5","author":"F Sebastian-Valles","year":"2024","unstructured":"Sebastian-Valles, F. et al. Time above range and no coefficient of variation is associated with diabetic retinopathy in individuals with type 1 diabetes and glycated hemoglobin within target. Acta Diabetol. https:\/\/doi.org\/10.1007\/s00592-024-02347-5 (2024).","journal-title":"Acta Diabetol."},{"key":"53112_CR27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00417-023-06275-y","volume":"262","author":"R Sotani-Ogawa","year":"2024","unstructured":"Sotani-Ogawa, R. et al. Continuous glucose monitoring metrics following sub-Tenon\u2019s injection of triamcinolone acetonide for diabetic macular edema. Graefes Arch. Clin. Exp. Ophthalmol. 262, 449\u2013456. https:\/\/doi.org\/10.1007\/s00417-023-06275-y (2024).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"53112_CR28","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.eprac.2024.01.011","volume":"30","author":"F Sebastian-Valles","year":"2024","unstructured":"Sebastian-Valles, F. et al. Effect of Christmas Holidays on Type 1 Diabetes Mellitus in Users of Glucose Flash Systems. Endocr. Pract. 30, 372\u2013379. https:\/\/doi.org\/10.1016\/j.eprac.2024.01.011 (2024).","journal-title":"Endocr. Pract."},{"key":"53112_CR29","doi-asserted-by":"publisher","first-page":"915482","DOI":"10.3389\/fendo.2022.915482","volume":"13","author":"K Guo","year":"2022","unstructured":"Guo, K. et al. Effect of the Chinese New Year Public Holiday on the Glycemic Control of T1DM With Intensive Insulin Therapy. Front. Endocrinol. (Lausanne). 13, 915482. https:\/\/doi.org\/10.3389\/fendo.2022.915482 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"53112_CR30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2337\/diacare.27.2.326","volume":"27","author":"HS Chen","year":"2004","unstructured":"Chen, H. S., Jap, T. S., Chen, R. L. & Lin, H. D. A prospective study of glycemic control during holiday time in type 2 diabetic patients. Diabetes Care. 27, 326\u2013330. https:\/\/doi.org\/10.2337\/diacare.27.2.326 (2004).","journal-title":"Diabetes Care"},{"key":"53112_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","volume":"44","author":"D Czock","year":"2005","unstructured":"Czock, D., Keller, F., Rasche, F. M. & H\u00e4ussler, U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet. 44, 61\u201398. https:\/\/doi.org\/10.2165\/00003088-200544010-00003 (2005).","journal-title":"Clin. Pharmacokinet."},{"key":"53112_CR32","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","volume":"42","author":"T Battelino","year":"2019","unstructured":"Battelino, T. et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 42, 1593\u20131603. https:\/\/doi.org\/10.2337\/dci19-0028 (2019).","journal-title":"Diabetes Care"},{"key":"53112_CR33","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s10384-018-0628-z","volume":"62","author":"Y Yamada","year":"2018","unstructured":"Yamada, Y. et al. Posterior subtenon infusion of triamcinolone acetonide as adjunctive treatment to panretinal photocoagulation using pattern scan laser for diabetic retinopathy. Jpn J. Ophthalmol. 62, 686\u2013692. https:\/\/doi.org\/10.1007\/s10384-018-0628-z (2018).","journal-title":"Jpn J. Ophthalmol."},{"key":"53112_CR34","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/s0161-6420(03)00475-5","volume":"110","author":"CP Wilkinson","year":"2003","unstructured":"Wilkinson, C. P. et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110, 1677\u20131682. https:\/\/doi.org\/10.1016\/s0161-6420(03)00475-5 (2003).","journal-title":"Ophthalmology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53112-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53112-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53112-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:33:16Z","timestamp":1783902796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-53112-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["53112"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-53112-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"15 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TH received personal fees from Novartis Pharma K.K., Bayer, Canon, Kowa Pharmaceutical, Senju Pharmaceutical, Chugai Pharmaceutical, and Santen Pharmaceutical. TM received personal fees from Novartis Pharma K.K., Bayer, Canon, Kowa Pharmaceutical, Senju Pharmaceutical, Chugai Pharmaceutical, Kyowa Kirin, and Santen Pharmaceutical. All other authors declare no conflicts of interest. The funding organizations had no role in the study design, data collection, analysis, or interpretation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21784"}}